Study of a targeted pill for PIK3CA-mutated advanced cancers
Part of Cancer, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a specific change in a gene called PIK3CA (found through a blood or tumor test).
- You have one of these cancer types: endometrial (uterine) cancer, breast cancer (hormone receptor-positive, HER2-negative or HER2-low), or another advanced solid tumor that hasn't responded to standard treatments.
- You have stopped responding to or couldn't tolerate at least one prior cancer treatment.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You must be able to do your daily activities with little or no help (ECOG score 0 or 1).
- You do not have poorly controlled diabetes or certain other gene changes (like PTEN, RAS, or BRAF).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
This trial tests a targeted pill called inavolisib for advanced or recurrent endometrial cancer that has a specific genetic change (PIK3CA mutation). The drug may block cancer growth by targeting this change, and the study aims to see if it helps people who have already tried platinum chemotherapy.
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
This trial tests an experimental drug called GenSci145, which may target cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments. The goal is to see if it can shrink tumors or slow cancer growth.
This study tests a new drug called LAE118, which targets cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments for advanced solid tumors, and the goal is to see if it is safe and can help shrink tumors.
This study tests a new drug called REC-7735 for people with solid tumors that have a specific genetic change (PIK3CA H1047R). The drug targets this change to try to stop the cancer from growing.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.